| | Seamless tech transfer from development to clinical production. |
| | Reduced production cost via development of optimal high yield bacterial, yeast, and insect cell expression systems. |
| | Ability to conduct "In-Parallel" cell line optimization using multiple cell lines simultaneously to reduce "time to cGMP." |
| | Cloning strategy and expression system development for high-level production of active, functional proteins. |
| | Selection of optimal clones and expression systems. |
| | Prokaryotic cGMP fermentation from 35 to 60 liters. |
| | Eukaryotic culture in roller bottles. |
| | Eukaryotic culture in 1 to 4 WAVE Bioreactors (25 liters each). Batch, Fed Batch, and Perfusion Culture Experience. |
| | Conversion of hybridomas for production in cell culture. |
| | Media optimization. |
| | Centrifuges for cell pelleting. |
| | Plaque assay and end point dilution for determination of viral titer. New assays can be developed to fulfill any requirement. |
| |
|